drugset
drugset / Trial / NCT03476928

A Study to Assess the Safety and Efficacy of Vilaprisan in Japanese Subjects With Uterine Fibroids and Heavy Menstrual Bleeding

NCT03476928 ↗

Phase 3 Terminated 153 enrolled Bayer
RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the safety and efficacy of vilaprisan in Japanese subjects with uterine fibroids and heavy menstrual bleeding (HMB).

Timeline

Start
2018-03-30
Primary completion
2021-07-12
Completion
2021-07-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Vilaprisan Other / unclassified 2 mg Oral

Indications

leiomyoma